	US 12,186,295 B2
	Ophthalmic compositions containing a nitric oxide releasing prostamide
Frédéric Pilotaz, Nice (FR); Alan L. Weiner, McKinney, TX (US); Marina Do, Menton (FR); and Julien Saldo, Cagnes sur Mer (FR)
Assigned to NICOX S.A., Valbonne (FR)
Filed by NICOX S.A., Valbonne (FR)
Filed on Jan. 11, 2021, as Appl. No. 17/146,057.
Application 17/146,057 is a continuation in part of application No. PCT/EP2019/068511, filed on Jul. 10, 2019.
Claims priority of application No. 18290082 (EP), filed on Jul. 12, 2018.
Prior Publication US 2021/0128458 A1, May 6, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/02 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/216 (2006.01); A61K 31/222 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/24 (2006.01); A61K 47/26 (2006.01)

CPC A61K 31/216 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 31/222 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01); A61K 47/186 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01)]

19 Claims

1. An ophthalmic aqueous composition in the form of solution comprising:

0.005% to 0.10% w/w hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester,

from 0.5% w/w to 1.5% w/w macrogol 15 hydroxystearate,

sodium phosphate dibasic heptahydrate,

boric acid,

a tonicity agent, and

water,

wherein a pH of the composition is 6, and

wherein macrogol 15 hroxystearate is the only solubilizing agent.